BRANFORD, Conn. / Sep 19, 2024 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that the Company will host an Investor & Analyst event in New York City on November 20th, 2024.
Quantum-Si’s management team will provide updates on the Company’s market opportunities, provide deeper insights into the technology roadmap including new instrument offerings and present data on novel uses of the company’s detection technology to applications beyond Next-Generation Protein Sequencing™.
The event will be live streamed over the internet and a question-and-answer session will follow the formal presentations.
EVENT DETAILS:
WHEN: Wednesday, November 20, 2024 | 10 AM – 12 PM EST
WHERE: Westin NY Times Square, 270 West 43rd Street, New York, NY, 10036
REGISTRATION LINK (both in-person & virtual): Quantum-Si Investor & Analyst Event
Investors interested in attending should contact QSI investor relations at This email address is being protected from spambots. You need JavaScript enabled to view it.. All other guests are invited to view the live or archived webcast virtually on the Investor Relations section of Quantum-Si’s website at https://ir.quantum-si.com/. The archived webcast will be available for at least 30 days following the event.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com or follow us on LinkedIn or X.
| Last Trade: | US$1.13 |
| Daily Change: | -0.02 -1.74 |
| Daily Volume: | 3,316,196 |
| Market Cap: | US$206.290M |
August 05, 2025 June 17, 2025 June 10, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
